Guardant Health (GH) Projected to Post Earnings on Thursday

Guardant Health (NASDAQ:GH) will likely be releasing its earnings data after the market closes on Thursday, February 20th. Analysts expect Guardant Health to post earnings of ($0.75) per share and revenue of $192.50 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Guardant Health Trading Up 2.4 %

Shares of GH opened at $48.12 on Tuesday. The business’s fifty day simple moving average is $39.25 and its two-hundred day simple moving average is $31.15. Guardant Health has a 12 month low of $15.81 and a 12 month high of $50.89. The company has a market cap of $5.95 billion, a price-to-earnings ratio of -11.35 and a beta of 1.32.

Wall Street Analyst Weigh In

Several brokerages have commented on GH. The Goldman Sachs Group increased their target price on Guardant Health from $36.00 to $49.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. Sanford C. Bernstein cut their target price on Guardant Health from $40.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 30th. Barclays began coverage on Guardant Health in a research note on Thursday, January 23rd. They set an “overweight” rating and a $60.00 target price on the stock. Guggenheim reiterated a “buy” rating on shares of Guardant Health in a research note on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. increased their price target on Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Sixteen analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $42.63.

Insider Buying and Selling

In related news, Director Musa Tariq sold 2,320 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the transaction, the director now directly owns 2,676 shares of the company’s stock, valued at approximately $93,660. This trade represents a 46.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders have sold 2,652 shares of company stock valued at $93,192. 5.50% of the stock is owned by company insiders.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.